Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - captopril - oral tablet - 12.5mg

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - captopril - oral tablet - 12.5mg

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - captopril - oral tablet - 12.5mg

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - captopril - oral tablet - 12.5mg

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - captopril - oral tablet - 12.5mg

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

multichem nz limited - captopril 12.5mg;   - tablet - 12.5 mg - active: captopril 12.5mg   excipient: colloidal silicon dioxide lactose maize starch microcrystalline cellulose palmitic acid purified talc

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

apotex nz ltd - captopril 12.5mg;   - tablet - 12.5 mg - active: captopril 12.5mg   excipient: croscarmellose sodium hydrated silica lactose monohydrate magnesium stearate microcrystalline cellulose - hypertension captopril is indicated for the treatment of hypertension in adult and paediatric patients. it may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are additive.

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - captopril - oral tablet - 12.5mg

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - captopril - oral tablet - 12.5mg

USA - engelsk - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - captopril (unii: 9g64rsx1xd) (captopril - unii:9g64rsx1xd) - captopril 12.5 mg - captopril tablets are indicated for the treatment of hypertension. in using captopril tablets, consideration should be given to the risk of neutropenia/agranulocytosis (see warnings). captopril tablets may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. in patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. captopril tablets are effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. the beneficial effect of captopril in heart failure does not require the presence of digitali